Gilead GILD has been a tremendous growth story ever since its HCV drug, Sovaldi/Harvoni, hit the market. Gilead’s HCV regimen is saving lives, which makes it a company of interest to competitors and regulators. Despite Sovaldi/Harvoni’s tremendous contributions to Gilead’s profits, GILD is up only 8% over the past year versus 12% for the biotech index IBB
The past is no longer prologue for GILD. The stock is a sell for the following reasons:
HCV Sales May Have Peaked
Gilead’s HCV regimen is becoming a victim of its own success. The faster sales grow, the less likely they will be able to maintain that growth rate going forward.
Source: Shock Exchange
Q3 product sales were flat Q/Q while HCV sales were down 2%. Sovaldi/Harvoni still represent over 58% of total product sales; as HCV goes, so goes Gilead. That’s problematic as it appears that HCV sales peaked in Q1. In the U.S., there appeared to be pent up demand for Harvoni as new starts tallied 70,000. Starts fell to 62,000 and 60,000 in Q2 and Q3, respectively. There is still untapped potential but management expects U.S. starts to flatten out next year.
Gilead generated $870 million in revenue in Europe from 50,000 starts. This compares unfavorably to the $1.1 billion in revenue on 30,000 starts in Q2; this implies that the price of Gilead’s HCV regimen has fallen off precipitously. Management expects revenue in Europe to be constrained by country specific budgets going forward. The fall off in European revenue was offset by $454 million in revenue from Japan. That said, due to the flattening of starts outside of Japan and declining prices in Europe, it appears that HCV revenue may have peaked.
Rate Hikes Could Be On The Way
GILD bulls must also realize that the overall market has been buoyed by zero interest rates and liquidity provided by the Fed. The Fed has been sending strong signals that it could raise rates in December for the first time in nearly a decade. The Fed has been preparing investors for months now, but that doesn’t mean the market will not sell off. A rate hike and a disappointing Q4 earnings seasons could send broader markets into a tailspin – taking GILD with it.
